DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Q-LINE BIOTECH LIMITED (QLINE) share price today?

Q-LINE BIOTECH LIMITED (QLINE) is trading at ₹531.4 on the NSE, down 1.20% on the day. Source: DocStoX.

What is the PE ratio of Q-LINE BIOTECH LIMITED?

Q-LINE BIOTECH LIMITED has a price-to-earnings (PE) ratio of 15.5 in the Healthcare sector.

What is the market capitalisation of Q-LINE BIOTECH LIMITED?

Q-LINE BIOTECH LIMITED has a market capitalisation of approximately ₹1,316 crore.

Q-LINE BIOTECH LIMITED

QLINE·NSE·Healthcare

₹531.40▼ -6.45 (-1.20%)

Healthcare · Medical Equipment

Revenue compounding 23% a year

Day₹525.00

₹546.50

52W₹431

₹60059%

Open

₹537.00

High

₹546.50

Low

₹525.00

Prev Close

₹537.85

Volume

78.0K

VWAP

₹535.94

Snapshot

Key fundamentals

Market Cap

₹1,316 Cr

P/E Ratio

15.52Fair

P/B Ratio

2.65

EPS

₹34.24

Book Value

₹209.24

ROE

25.90%Strong

ROCE

22.00%Efficient

Dividend Yield

0.00%

Debt / Equity

0.75Moderate

Face Value

₹10.00

52W High

₹600.00

52W Low

₹431.00

Sector

Healthcare

Industry

Medical Equipment

Avoid

Narrow moatMedium uncertainty

Fair value estimate

₹378

▼ 28.8%downside

Trading at ₹531 — 29% above our estimate

BearFair valueBull

₹322₹378₹435

/100

Business quality — Solid

Growth 87Profitability 90Efficiency 35Valuation 74

Plain English

Our view

Revenue compounding 23% a year
Strong returns on equity (26%)
Fundamental red flags (Piotroski 1/9)

Strengths

Strong returns on equity (26%)
Capital is working hard (ROCE 22%)
Revenue compounding 23% over 3 years
Profit growing 21% a year

Risks

Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

26% ROE fading to 13% over ~10 yrs, on ₹209 book

₹372

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹401

Analyst target

No analyst coverage

—

Blended fair value₹378

What the numbers say

Investment thesis

Bull case

Strong returns on equity (26%)
Capital is working hard (ROCE 22%)
Revenue compounding 23% over 3 years
Profit growing 21% a year
Promoters hold a controlling stake

Bear case

Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

15.5Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

25.9%Strong

Above 15% is considered healthy for Indian equities

ROCE

22.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.75Moderate

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹1,316 Cr

P/B

2.65

EPS

₹34.24

Div Yield

—

What changed

Recent changes

Foreign investors+1.7% stake last quarter
Domestic institutions+10.1% stake last quarter
Promoters-29.26% stake last quarter

What matters

News impact

Overview

Valuation

Attractive

P/E 15.5×

Growth

Strong

+23% rev CAGR

Profitability

Excellent

25.9% ROE

Financial health

Comfortable

D/E 0.75

Momentum

N/A

No technicals

Today

Trading activity

Delivery %81.5%

Turnover₹418.03L Cr

Trades131

VWAP₹535.94

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+23.2%

—

10Y

—

Profit

+20.5%

—

10Y

—

EPS

-44.8%

—

10Y

—

Profile

Pros

Company has a good return on equity (ROE) track record: 3 Years ROE 25.2%

Watch-outs

Cons

Debtor days have increased from 92.7 to 134 days.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 May 2026

Promoters trimmed their stake by 29.26 pts; foreign investors bought 1.67 pts; domestic institutions added 10.14 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

68%

Promoter

Promoters

67.5%-29.26

Public

16.0%+15.97

FII / FPI

1.7%+1.67

DII

10.1%+10.14

Others

4.7%

Total shareholders

3,497+3,497 QoQ

Quarterly trend

Ownership over time

Q1 FY27

Promoter67.51%

FII1.67%

DII10.14%

Public15.97%

Others4.71%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 2010, Q-Line Biotech Ltd. is engaged in the business of developing, manufacturing and marketing a diverse range of reagents.[1]